Taking a Daily Vitamin to Prevent Type 1 Diabetes?

Department of Pathology, University of Florida, Gainesville, Florida, USA.
Diabetes (Impact Factor: 8.1). 02/2009; 58(1):24-5. DOI: 10.2337/db08-1479
Source: PubMed
Download full-text


Available from: Clive Wasserfall,
  • Source
    • "Recently, retinoid treatment has been successfully employed in patients suffering from lupus nephritis, a major manifestation of SLE (Kinoshita et al., 2010). Moreover, epidemiological studies suggest that either vitamin A or D may be beneficial in the treatment of patients with high risk of type 1 diabetes (T1D) (Wasserfall and Atkinson, 2009). ATRA is able to prevent overt "
    [Show abstract] [Hide abstract]
    ABSTRACT: Retinoids play important roles in the transcriptional activity of normal, degenerative and tumour cells. Retinoid analogues may be promising therapeutic agents for the treatment of immune disorders as different as type I diabetes and systemic lupus erythematosus. In addition, the use of retinoids in cancer treatment has progressed significantly in the last two decades; thus, numerous retinoid compounds have been synthesized and tested. In this paper, the actual or potential use of retinoids as immunomodulators or tumour-suppressive agents is discussed.
    British Journal of Pharmacology 05/2012; 167(3):483-92. DOI:10.1111/j.1476-5381.2012.02031.x · 4.84 Impact Factor
  • Source

    Diabetes care 10/2009; 32(10):1769-82. DOI:10.2337/dc09-0374 · 8.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is accumulating evidence that shows the metabolism of zinc and vitamin A are altered in diabetes mellitus type I (DMTI), thus the present study was conducted to evaluate the effects of combination of zinc and vitamin A supplementation on serum fasting blood sugar (FBS), insulin, apoprotein B and apoprotein A-I in patients with DMTI. Forty-eight, 7-year-old to 20-year-old patients with at least 2 years of DMTI history, without any metabolic condition or medicine intake with insulin treatment, participated in a randomized double-blind clinical trial for 12 weeks. They were divided into zinc and vitamin A (VAZ)-supplemented (10 mg elemental zinc per day and one-half of a 25,000 IU vitamin A tablet every other day) and/or placebo groups after matching for sex, age and DMTI duration. Nutrient intake was estimated using 24 h recall and was analyzed by food processor program. Serum apoproteins B and A-I, FBS and insulin levels were determined at the beginning and end of the trial. There was significant increase in apoprotein A-I (P < 0.0001) and a significant decrease in apoprotein B (P < 0.0001) and apoprotein B/apoprotein A-I ratio (P < 0.0001) at the end of the study compared with baseline values in the VAZ group but apoprotein A-I had a significant increase (P < 0.0001) and the apoprotein B/apoprotein A-I ratio had a significant decrease (P = 0.02) at the end of study in the VAZ group compared with the control group It seems that combined zinc and vitamin A supplementation can improve serum apoprotein A-I, apoprotein B and the apoprotein B/apoprotein A-I ratio in patients with DMTI.
    International Journal of Food Sciences and Nutrition 03/2010; 61(2):182-91. DOI:10.3109/09637480903334171 · 1.21 Impact Factor
Show more